WallStSmart
ABT

Abbott Laboratories

NYSE: ABT · HEALTHCARE · MEDICAL DEVICES

$90.79
-0.59% today

Updated 2026-04-29

Market cap
$158.36B
P/E ratio
25.53
P/S ratio
3.51x
EPS (TTM)
$3.57
Dividend yield
2.64%
52W range
$91 – $136
Volume
11.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Abbott Laboratories (ABT) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$90.79
Consensus
$137.71
+51.68%
2030 Target
$462.92
+409.88%
DCF
$87.68
-4.20% MoS
17 analysts:
8 Buy2 Hold0 Sell

Management guidance

Abbott completed the $23B Exact Sciences acquisition (closed March 23, 2026), expected to contribute $3B in incremental revenue to Abbott in 2026. No specific CEO revenue targets for 2027-2030 were disclosed in available guidance, but management has emphasized strong growth drivers: FreeStyle Libre CGM expansion, Nutrition segment recovery (Ensure brand), and cancer diagnostics market penetration ($60B TAM).

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$761.24
$66.1B Rev × 20x P/S
Base case (2030)
$462.92
$66.1B Rev × 12x P/S
Bear case (2030)
$308.61
$66.1B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$40.1B$42.0B$44.3B$48.8B$52.6B$56.9B$61.4B$66.1B
Revenue growth—4.6%5.7%10.1%7.8%8.1%7.9%7.7%
EPS$4.44$4.67$4.90$5.74$6.32$6.95$7.62$8.35
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$339.47$370.33$390.91$421.77$462.92

Catalysts & risks

Growth catalysts
+ Exact Sciences integration delivering $3B incremental revenue in 2026; Cologuard and Oncotype DX cancer screening portfolio expansion
+ FreeStyle Libre CGM system continued adoption driven by clinical evidence (reduced heart hospitalizations in Type 2 diabetes patients)
+ Precision Oncology platform integration with Flatiron's OncoEMR in 1,600+ U.S. community cancer centers driving clinician adoption
+ Nutrition segment recovery post-pandemic normalization; Ensure brand stabilization
+ Strategic investment in Whoop ($575M Series G) signals expansion into digital health and preventive care ecosystem
+ Diabetes Care franchise growth acceleration; CGM market share gains vs. competitors (DexCom, Medtronic)
Key risks
- NEC (Necrotizing Enterocolitis) infant formula litigation against Similac could result in significant settlements/damages and reputational harm
- Exact Sciences integration execution risk; customer churn post-acquisition; dilution of earnings in near term
- Currency headwinds in international markets; China pricing pressure and potential tariff impacts on margins
- Competitive pressure in diagnostics and CGM segments from DexCom, Medtronic, and emerging players
- Regulatory setbacks in cancer screening or diabetes devices; FDA clearance delays
- Macro slowdown impacting hospital capital spending and elective procedures in developed markets

Methodology

Abbott Laboratories's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 17 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.